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Abstract 
Review on translocations in small cell carcinoma, 
with data on clinics, genetics and cytogenetics. 
Classification 
In the group of malignant epithelial tumours of the 
lungs, small cell carcinomas (small cell lung cancer 
(SCLC)) are usually opposed to non-small cell 
carcinomas (non-small cell lung cancer (NSCLC)). 
Small cell carcinoma is a pulmonary 
neuroendocrine tumour.  
Other neuroendocrine tumours of the lungs are 
large cell neuroendocrine carcinomas, typical 
carcinoids, and atypical carcinoids. 
Clinics and pathology 
Disease 
Lung small cell carcinoma 
Epidemiology 
Small cell carcinomas comprise about 15-20% of 
lung cancers.  
Small cell carcinoma is more often associated with 
tobacco smoking than adenocarcinoma, and less 
than squamous cell carcinoma. 
Clinics 
Patients are typically men older than 60-70 years. 
Small cell carcinoma more often presents with 
symptoms of early metastases.  
Location of the tumour is usually central, but SCLC 
may occur in a peripheral location.  
Bronchoscopic biopsy is often positive (van 
Meerbeeck et al., 2011). 
Cytology 
Small round or oval cells with a finely granular 
nucleus and frequent mitoses. 
Pathology 
Immunohistochemistry is often positive for 
neuroendocrine markers, such as chromogranin, 
synaptophysin, and CD56; SCLCs are also positive 
for NKX2-1 (14q13, also called TTF-1, a tissue-
specific transcription factor in lung epithelial cells) 
in most cases. 
Prognosis 
Although SCLC is extremely sensitive to initial 
chemotherapy and radiotherapy, most patients 
eventually relapse. SCLC is an aggressive disease 
with poor prognosis, with a five years survival of 
5%. High expression of SOX2 (3q26) and FGFR1 
(8p11) are associated with the worst outcome 
(Yang et al., 2013). 
Genetics 
Note 
TP53 (17p13) mutations are detected in 70 to 90% 
of SCLCs. RB1 (13q14) and the retinoblastoma 
pathway are inactivated in most SCLCs. PTEN 
(10q23) is mutated in 2 to 10%. MYC (8q24) 
amplifications and amplification of MYC family 
members are found in 30% of SCLCs in pre-
invasive stages. Loss of heterozygocity (LOH) on 
chromosome arm 3p is found in more than 80% of 
SCLCs, including the loss of FHIT (3p14) protein 
expression. FHIT controls the invasive phenotype 
of lung cancer cells by regulating the expression of 
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FHIT loss confers cisplatin resistance in lung 
cancer via the AKT/NF-KB/SLUG pathway (Wu et 
al., 2014). In wide genomic analyses, an elevated 
rate of C:G>A:T transversions were found, 
compared to neutral mutations, consistent with 
demonstrated effects of tobacco smoke carcinogens 
on DNA. SOX2, a transcription factor, one of the 
genes able to reprogram human somatic cells to 
pluripotent stem cells (Lin et al., 2011) was 
amplified in 27% of the samples. A recurrent 
RLF/MYCL translocation was found in 9% of 
SCLCs, and the RLF/MYCL fusion overexpressed 
MYCL (1p34). FGFR1 was amplified in 6%. 
Chromatin-modifying enzymes such as EP300 
(22q13) were frequently mutated (Peifer et al., 
2012; Rudin et al., 2012). To be noted that SOX2 
and FGFR1 are also known to be implicated in a 
subset of squamous cell carcinoma of the lung 
(Pietanza and Ladanyi, 2012). In contrast with lung 
adenocarcinomas, there is no molecularly targeted 
agents yet for small cell carcinomas of the lung. 
Cytogenetics 
Note 
Only a few genes have been found implicated in 
many different translocations:  
- RLF (1p34), a zinc finger protein, which may be 
involved in transcriptional regulation. Depletion of 
Rlf leads to DNA hypermethylation in the mouse. 
RLF is likely to be involved in epigenetic processes 
(Daxinger et al., 2013), RLF is translocated with 10 
different partners (herein below) in SCLCs; 
- BCL2L1 (20q11) an inhibitor of cell death, 
involved in various cancers, translocated with 7 
different partners (herein below) in SCLCs; 
- PVT1 (8q24), a non-protein coding and oncofetal 
gene, translocated with various partners in: breast 
cancer, Ewing/PNET spectrum, and hematological 
malignancies, and with 7 different partners (herein 
below) in SCLCs; PVT1 is a hotspot for 
chromosomal breaks during MYC amplification 
(L'Abbate et al., 2014). 
- Other genes recurrently found are HM13 (20q11), 
translocated with 3 different partners, and MYCL, 
BMP8B (1p34), CAP1 (1p34), CREBBP (16p13), 
and DNM2 (19p13), implicated twice each. 
Cytogenetics Morphological 
Fusion transcripts were often found in amplified 
regions in 1p34, 2p24, 8q24, and 9p24, suggesting 
that amplification and fusion of genes occur 
simultaneously by chromothripsis (Iwakawa et al., 
2013). One hundred translocations have so far been 
reported in small cell carcinoma of the lung. They 
are the following:  




t(1;1)(p36;p34) RLF/FAM132A (Iwakawa et al., 
2013) 
t(1;1)(p36;p34) RLF/UBE2J2 (Iwakawa et al., 
2013) 
t(1;1)(p35;p35) SERINC2/ZCCHC17 (Rudin et al., 
2012) 
inv(1)(p34p34) BMP8B/RLF (Rudin et al., 2012) 
inv(1)(p34p34) CAP1/BMP8B (Rudin et al., 2012) 
inv(1)(p34p34) RLF/PPT1 (Rudin et al., 2012) 
t(1;1)(p34;p34) CAP1/MACF1 (Iwakawa et al., 
2013) 
t(1;1)(p34;p34) INPP5B/SF3A3 (Rudin et al., 
2012) 
t(1;1)(p34;p34) inv(1)(p34p34) RLF/MYCL (Rudin 
et al., 2012; Iwakawa et al., 2013) 
t(1;1)(p34;p34) RLF/COL9A2 (Iwakawa et al., 
2013) 
t(1;1)(p34;p34) RLF/SMAP2 (Iwakawa et al., 
2013) 
t(1;1)(p34;p34) SF3A3/GNL2 (Iwakawa et al., 
2013) 
t(1;1)(p34;p34) SMAP2/MYCL (Iwakawa et al., 
2013) 
t(1;1)(p34;p34) ZMPSTE24/MFSD2A (Iwakawa et 
al., 2013) 
t(1;1)(q21;q21) TXNIP/NOTCH2NL (Rudin et al., 
2012) 
t(1;1)(q25;q25) XPR1/TRMT1L (Iwakawa et al., 
2013) 
del(1)(q44q44) ZNF695/TFB2M (Rudin et al., 
2012) 
t(1;12)(p34;q24) TRIT1/EP400 (Iwakawa et al., 
2013) 
t(1;19)(p36;q13) UBE4B/TBCB (Iwakawa et al., 
2013) 
t(1;20)(p34;q11) BCL2L1/BMP8B (Iwakawa et al., 
2013) 
t(1;20)(p34;q11) BCL2L1/DEM1 (Iwakawa et al., 
2013) 
t(1;20)(p34;q11) BCL2L1/RIMS3 (Iwakawa et al., 
2013) 
t(1;20)(p34;q11) BCL2L1/RLF (Iwakawa et al., 
2013) 
t(1;20)(p34;q11) BCL2L1/ZNF643 (Iwakawa et al., 
2013) 
t(1;20)(p34;q11) BCL2L1/ZNF684 (Iwakawa et al., 
2013) 
t(1;20)(p34;q11) PPT1/BCL2L1 (Iwakawa et al., 
2013) 
t(1;20)(p34;q11) RLF/HM13 (Iwakawa et al., 2013) 
t(2;5)(p22;q14) BIRC6/BHMT2 (Rudin et al., 
2012) 
t(2;6)(q31;p12) RCAN2/RAPGEF4 (Rudin et al., 
2012) 
t(2;12)(p23;p13) CACNA2D4/WDR43 (Campbell 
et al., 2008) 
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t(3;3)(p21;q23) RASA2/NICN1 (Iwakawa et al., 
2013) 
t(3;3)(q13;q22) STAG1/STXBP5L (Iwakawa et al., 
2013) 
del(3)(q23q23) SPSB4/ACPL2 (Rudin et al., 2012) 
t(3;3)(q23;q24) SLC25A36/PLSCR1 (Iwakawa et 
al., 2013) 
t(3;3)(q26;q26) GPR160/NCEH1 (Peifer et al., 
2012) 
inv(3)(q26q27) DCUN1D1/ATP11B (Rudin et al., 
2012) 
del(3)(q28q28) LPP/TPRG1 (Rudin et al., 2012) 
t(3;11)(p24;p15) NGLY1/CCKBR (Iwakawa et al., 
2013) 
t(3;11)(p22;q14) DLEC1/ODZ4 (Iwakawa et al., 
2013) 
t(3;11)(p21;p15) SFMBT1/AP2A2 (Iwakawa et al., 
2013) 
t(3;12)(q13;p11) NAA50/MRPS35 (Rudin et al., 
2012) 
t(3;16)(q21;p13) TXNDC11/RUVBL1 (Rudin et 
al., 2012) 
t(3;17)(q11;q21) NPEPPS/EPHA6 (Rudin et al., 
2012) 
t(5;5)(q13;q13) NAIP/OCLN (Iwakawa et al., 
2013) 
t(5;5)(q31;q31) SKP1/CDKL3 (Rudin et al., 2012) 
t(5;5)(q31;q31) JADE2/UBE2B (Iwakawa et al., 
2013) 
del(6)(q21q22) CEP85L/SCML4 (Rudin et al., 
2012) 
t(6;8)(p21;p21) HMBOX1/ZFAND3 (Iwakawa et 
al., 2013) 
t(6;20)(p21;p12) CRLS1/KCNK17 (Iwakawa et al., 
2013) 
del(7)(p21p21) ANKMY2/ISPD (Rudin et al., 
2012) 
t(8;8)(q12;q24) PVT1/CHD7 (Campbell et al., 
2008; Pleasance et al., 2010) 
t(8;8)(q12;q24) PVT1/CLVS1 (Iwakawa et al., 
2013) 
inv(8)(q22q23) OXR1/COX6C (Rudin et al., 2012) 
inv(8)(q22q23) YWHAZ/OXR1 (Rudin et al., 
2012) 
t(8;8)(q23;q23) NUDCD1/SYBU (Iwakawa et al., 
2013) 
t(8;8)(q23;q24) CSMD3/MYC (Iwakawa et al., 
2013) 
t(8;8)(q23;q24) PTK2/PKHD1L1 (Iwakawa et al., 
2013) 
t(8;8)(q24;q24) PVT1/LY6H (Iwakawa et al., 2013) 
t(8;14)(p23;q22) AGPAT5/TXNDC16 (Rudin et 
al., 2012) 
t(8;14)(q24;q11) PVT1/CCNB1IP1 (Iwakawa et al., 
2013) 






t(8;14)(q24;q11) PVT1/SLC7A7 (Iwakawa et al.,  
2013) 
t(8;18)(q24;q12) PVT1/NOL4 (Iwakawa et al., 
2013) 
t(9;9)(p24;p24) KANK1/DOCK8 (Rudin et al., 
2012) 
t(9;9)(p24;p24) RIC1/JAK2 (Iwakawa et al., 2013) 
t(10;10)(p12;p12) WAC/GPR158 (Iwakawa et al., 
2013) 
t(10;10)(p11;q21) CCDC7/UBE2D1 (Rudin et al., 
2012) 
t(10;10)(q21;q21) CCDC6/CTNNA3 (Rudin et al., 
2012) 
t(11;11)(p15;q23) ATP5L/TEAD1 (Iwakawa et al., 
2013) 
t(11;11)(q14;q14) PICALM/CCDC81 (Iwakawa et 
al., 2013) 
t(11;11)(q14;q14) GAB2/NARS2 (Rudin et al., 
2012) 
t(12;12)(p13;p13) ENO2/ACRBP (Iwakawa et al., 
2013) 
inv(12)(p13p13) ERC1/ANO2 (Rudin et al., 2012) 
inv(12)(p13p13) C12orf4/CD9 (Rudin et al., 2012) 
del(12)(p13p13) ANO2/FBXL14 (Rudin et al., 
2012) 
del(12)(q12q13) RPAP3/SCAF11 (Rudin et al., 
2012) 
t(12;12)(q14;q21) PAWR/GNS (Iwakawa et al., 
2013) 
t(12;12)(q23;q23) CHPT1/UTP20 (Rudin et al., 
2012) 
t(12;12)(q24;q24) CIT/RFC5 (Iwakawa et al., 
2013) 
t(12;12)(q24;q24) NCOR2/SCARB1 (Iwakawa et 
al., 2013) 
t(14;14)(q23;q23) MTHFD1/SYNE2 (Rudin et al., 
2012) 
t(14;16)(q32;q12) SMEK1/HEATR3 (Iwakawa et 
al., 2013) 
t(15;15)(q21;q21) SPG11/SORD (Iwakawa et al., 
2013) 
t(16;16)(p13;p13) CREBBP/RHBDF1 (Peifer et al., 
2012; Iwakawa et al., 2013) 
t(16;16)(p13;p13) del(16)(p13p13) CREBBP/SLX4 
(Pleasance et al., 2010) 
t(17;17)(p11;p13) MPRIP/TP53 (Peifer et al., 2012) 
t(17;17)(q25;q25) LRRC45/GCGR (Iwakawa et al., 
2013) 
t(17;17)(q25;q25) FOXK2/HEXDC (Iwakawa et 
al., 2013) 
t(18;18)(p11;q12) TWSG1/PIK3C3 (Iwakawa et 
al., 2013) 
t(19;19)(p13;p13) NFIX/GATAD2A (Iwakawa et 
al., 2013) 
t(19;19)(p13;p13) DNM2/ILF3 (Rudin et al., 2012) 
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inv(19)(p13p13) GIPC1/PKN1 (Rudin et al., 2012) 
del(19)(q13q13) PPP1R37/KLC3 (Rudin et al., 
2012) 
t(20;20)(q11;q11) BCL2L1/HM13 (Iwakawa et al., 
2013) 
t(20;20)(q11;q11) TPX2/HM13 (Iwakawa et al., 
2013) 
inv(20)(q11q13) CEP250/DPM1 (Rudin et al., 
2012) 
inv(22)(q13q13) TTLL1/TSPO (Rudin et al., 2012) 
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